text
"['\nIX. 계열회사 등에 관한 사항\n1.\xa0계열회사에 관한 사항\xa0(1)\xa0기업집단의 명칭 : 종근당그룹\xa0(2) 계열회사간 출자현황\n(2021.3.31 현재)\n회\xa0 사\xa0 명\n투자지분 현황\n비\xa0 고\n1\n(주)종근당홀딩스(113-81-06667)\n종근당산업(주) 57.55%, (주)벨이앤씨 42.38%,(주)벨커뮤니케이션즈 51.00%, 종근당건강(주) 51.00%,(주)경보제약 43.41%, (주)종근당바이오 39.11%,(주)종근당 24.39%, (주)벨아이앤에스 40.00%\xa0\n상장\n2\n(주)종근당(110-86-08069)\nPT CKD OTTO PHARMACEUTICALS 70.00%\n상장\n3\n종근당바이오(주)(110-81-53652)\nPacific Blue Health Pty Ltd 100.00%\n상장\n4\n(주)경보제약(312-81-04567)\n-\n상장\n5\n종근당산업(주)(110-81-07992)\n-\n비상장\n6\n(주)벨이앤씨(124-81-47431)\n-\n비상장\n7\n(주)벨커뮤니케이션즈(110-81-33831)\n-\n비상장\n8\n종근당건강(주)(134-81-29992)\n(주)텔라이프 50.00%, (주)에이뉴힐 100.00%, (주)씨에이치랩스 50.00%Qingdao Zhong Gen Tang Health Co., Ltd 100.00%\n비상장\n9\nCKD창업투자(주)(306-81-29961)\n-\n비상장\n10\n(주)벨에스엠(107-86-80124)\n-\n비상장\n11\n(주)벨아이앤에스(110-81-82195)\n-\n비상장\n12\n(주)텔라이프(741-88-00832)\n-\n비상장\n13\n(주)에이뉴힐(773-87-01224)\n-\n비상장\n14\n(주)씨에이치랩스(513-81-91331)\n-\n비상장\n15\nPT CKD OTTO PHARMACEUTICALS\n-\n해외법인\n16\nPacific Blue Health Pty Ltd(구 CKDBio Australia Pty Ltd)\n-\n해외법인\n17\nQingdao Zhong Gen Tang Health Co., Ltd\xa0\n-\n해외법인\n2. 타법인 출자현황\n[2021. 3. 31 현재]\n(단위 : 주, 백만원, 천달러, 백만루피아, %)\n법인명\n출자목적\n기초잔액\n증가(감소)\n당분기말 잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한국능률협회컨설팅(비상장)\n단순투자\n39,195\n4.9\n196\n-\n-\n-\n39,195\n4.9\n196\n76,516\n6,331\n매일방송(비상장)\n""\n542,210\n1.0\n2,643\n-\n-\n-\n542,210\n1.0\n2,643\n393,311\n1,891\n코리아이플랫폼(비상장)\n""\n116,659\n1.6\n951\n-\n-\n-\n116,659\n1.6\n951\n143,653\n3,191\n씨앤비인터내셔널(비상장)\n""\n30,000\n10.0\n531\n-\n-\n-\n30,000\n10.0\n531\n8,943\n(7,190)\nKC상생투자조합\n""\n-\n2.4\n974\n-\n-\n-\n-\n2.4\n974\n38,995\n2,293\nCARA (미국_상장)\n""\n75,597\n0.2\n1,244\n-\n-\n616\n75,597\n0.2\n1,860\n$271,157\n$8,410\nLARIMAR(미국_상장)\n""\n14,312\n0.1\n333\n-\n-\n(96)\n14,312\n0.1\n237\n$104,686\n($42,482)\n(주)한미약품(상장)\n""\n2,177\n0.0\n798\n43\n-\n(95)\n2,220\n0.0\n703\n1,502,398\n3,019\nBioMX(미국_상장)\n""\n499,324\n2.2\n3,466\n-\n-\n564\n499,324\n2.1\n4,030\n$70,363\n($30,086)\n동양레저(비상장)\n""\n20,000\n0.6\n100\n-\n-\n-\n20,000\n0.6\n100\n63,052\n7,993\n스카이랩스(비상장)\n""\n8,733\n7.9\n2,500\n-\n-\n-\n8,733\n7.9\n2,500\n4,319\n(400)\nRMGP Bio Pharma(비상장)\n""\n-\n18.9\n4,526\n-\n666\n-\n-\n18.9\n5,192\n$22,497\n($5,156)\nCKD-BS Start-Up벤처투자조합\n""\n-\n3.4\n630\n-\n330\n-\n-\n3.3\n960\n17,443\n(542)\nPT CKD OTTO PHARMACEUTICALS(인도네시아_비상장)\n합작\n100,800,000\n70.0\n387\n-\n-\n(387)\n100,800,000\n70.0\n-\nIDR 315,371\n(IDR 49,785)\n합 계\n-\n-\n19,279\n43\n996\n602\n-\n-\n20,877\n-\n-\n주) 당분기말 현재 해당 법인에 대한 출자비율이 5% 미만이거나, 장부가액이 1억원 미만인 경우 기재를 생략하였습니다.\n']"
